Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.51 |
| ▸ | TUBB | P07437 | 5/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324870 | 1.00 | EGFR (0.58) | EGFRCYP1A1CYP1A2CYP1B1HTR1A | |
| SCHEMBL1324862 | 1.00 | EGFR (0.58) | EGFRCYP1A1CYP1A2CYP1B1HTR1A | |
| SCHEMBL1122677 | 0.82 | ALDH1A1 (0.68) | EGFRCYP1A1CYP1A2CYP1B1HTT | |
| SCHEMBL1122375 | 0.80 | EGFR (0.59) | EGFRCYP1A1CYP1A2CYP1B1HTR1A | |
| SCHEMBL1324310 | 0.80 | EGFR (0.59) | EGFRCYP1A1CYP1A2CYP1B1HTR1A | |
| SCHEMBL1122374 | 0.80 | EGFR (0.59) | EGFRCYP1A1CYP1A2CYP1B1HTR1A | |
| SCHEMBL1324314 | 0.80 | EGFR (0.59) | EGFRCYP1A1CYP1A2CYP1B1HTR1A | |
| SCHEMBL1324660 | 0.80 | PSMB11 (0.60) | HTR1AGAAHTTKDM4EALDH1A1 | |
| SCHEMBL1324658 | 0.80 | PSMB11 (0.60) | HTR1AGAAHTTKDM4EALDH1A1 | |
| SCHEMBL1324787 | 0.80 | PSMB11 (0.60) | HTR1AGAAHTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773310-B9 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2012-04-25 | — | — | EP | claimed |
| US-8058313-B2 | 4-((1E)-2-(((E)-2-fluoro-4-cyanostyrylsulfonyl)methylsulfonyl)vinyl)-3-fluoro-benzonitrile; mitogen activated protein kinase inhibitor; cell growth factor receptor antagonist; angiogenesis inhibitor, antiproliferative and anticarcinogenic agent; neurodegenerative diseases | Temple University—Of the Commonwealth System of Higher Education (US) | 2011-11-15 | — | — | US | claimed |
| EP-1773310-B1 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-10-19 | — | — | EP | claimed |
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-20 | — | — | US | claimed |
| EP-1773310-B9 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1773310-B1 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | DEGS1, SULT1E1, PTDSS1 | EGFR 694/4885CYP1A1 1563/4885CYP1A2 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.